GLP-1 medicines and birth control: why the exact drug matters

Begin with both medication names and how you take them

“A weekly injection” and “the pill” leave out information the pharmacist needs. Record the name of the GLP-1 medicine, whether it is a branded or compounded product, and the name and route of your contraception. Bring both labels to the conversation. A platform name alone does not identify the prescription.

Our guide to medication names, doses and concentrations explains how to keep those details straight. Identifying a medicine is the first step; deciding what to do about an interaction belongs with the care team.

Ask before the first prescription, before a planned increase and when switching medicines. Advice supplied for a previous product should be checked against the new one, even if the reason you are taking it remains weight management.

Three current US labels illustrate the differences

These examples summarize product labeling checked September 9, 2026. They are not a complete list of GLP-1 medicines or a personal contraception plan. Read the instructions for your own prescription with a clinician.

• Zepbound, containing tirzepatide: for people taking oral hormonal contraception, its label recommends changing to a non-oral method or adding a barrier method during the four weeks following treatment initiation and each dose increase. It links this precaution to delayed stomach emptying.
• Foundayo, containing orforglipron: its label specifies a non-oral method or additional barrier protection for 30 days after starting and after each increase. The label says the effect on oral-contraceptive absorption has not been evaluated in a clinical trial; the precaution addresses the potential effect of delayed stomach emptying.
• Wegovy, containing semaglutide: its clinical-pharmacology section reports no clinically significant pharmacokinetic differences for the contraceptive components ethinyl estradiol and levonorgestrel studied with semaglutide. That finding is not a guarantee about every contraceptive product or every circumstance, including missed pills or gastrointestinal illness.

A precaution is not a measured pregnancy rate

A study of drug absorption measures what happens to medicine exposure. It does not automatically tell you how frequently pregnancies occur in everyday use. Likewise, a precaution in a label can reflect uncertainty that needs a practical response. Avoid turning either into an unsupported “common failure” statistic.

Keep dates attached to advice. Some widely shared guidance was written before newer medicines became available. The Foundayo example shows why a statement about the products considered in an older document cannot substitute for checking a current prescription.

The Zepbound and Foundayo labels say hormonal methods that are not taken orally should not be affected by this interaction. That addresses the route-related concern. A clinician still needs to help choose a suitable method and explain its use; this article does not recommend a particular contraceptive.

Vomiting or diarrhea raises a different pill question

The FSRH patient leaflet, hosted by the College of Sexual and Reproductive Healthcare, explains that vomiting and diarrhea can reduce contraceptive-pill effectiveness. This can matter separately from a direct drug interaction. Follow the missed-pill or illness instructions for your exact contraceptive and ask a pharmacist for help interpreting them.

Tell the pharmacist when you took the pill, when symptoms occurred and whether you missed any tablets. Do not assume a reassurance about semaglutide and drug exposure means illness can be ignored. Different pills have different instructions, so a general article should not invent one replacement-pill schedule.

If you think protection may have failed and emergency contraception could be needed, seek prompt advice from a pharmacist, sexual-health service or clinician. CDC guidance explains that the available options depend on timing and method. Provide all medication names; do not wait for a routine weight-management follow-up to ask.

Backup contraception and pregnancy planning use different timelines

A backup period after starting treatment is not the same as the time a medicine needs to be stopped before trying to conceive. Ask for a separate pre-pregnancy plan covering the exact product and any other conditions being treated.

For example, the Wegovy label instructs discontinuation at least two months before a planned pregnancy when used for weight reduction or cardiovascular risk reduction. Do not apply that interval to every GLP-1 product. When pregnancy is recognized during weight-loss treatment, the Wegovy, Zepbound and Foundayo labels direct discontinuation; contact the prescriber promptly to arrange appropriate care.

If you also receive diabetes treatment, tell the clinician managing it so your broader care can be coordinated. An unexpected pregnancy calls for a medication review, not an assumption that an outcome is already known.

What to bring to a CoreAge Rx consultation

CoreAge Rx’s medical intake instructions request health history, current medicines and allergies for provider review. Include your contraception, pregnancy intentions and any recent contraceptive problems. Ask the clinician to address those details before deciding on a prescription.

The official CoreAge Rx site describes compounded semaglutide and tirzepatide offerings. The Foundayo example above is general medication education, not a claim that CoreAge Rx supplies that product. Our CoreAge Rx review links this medication research to an investigation of the service.

For routine follow-up, CoreAge Rx describes portal messaging with typical responses in one to three business days. Clarify contraception before starting or changing treatment; use timely local clinical or pharmacy advice for a possible contraceptive failure or pregnancy concern rather than relying on that routine response window.

FDA explains that compounded GLP-1 drugs are not approved and should be used only when an approved drug cannot meet a patient’s medical needs. A familiar ingredient name does not make a compound equivalent to a branded product. Ask the prescriber and dispensing pharmacy how the relevant precautions apply to the actual prescription.

Common questions

Keep researching

• Identify names, amounts and concentration on a label
• Review CoreAge Rx service information
• Explore more medication guides